2024/03/14 更新

写真a

サクマ ナオコ
佐久間 直子
Sakuma Naoko
所属
付属病院 耳鼻咽喉科・頭頚部外科 講師
職名
講師
外部リンク

学位

  • 博士(医学) ( 横浜市立大学 )

研究分野

  • ライフサイエンス / 耳鼻咽喉科学

論文

  • 突発性難聴初期治療後に対する二次治療の上乗せ効果の検討

    鈴木 宏隆, 松延 毅, 佐久間 直子, 臼倉 典宏, 青木 秀治, 大久保 公裕

    日本耳科学会総会・学術講演会抄録集   33回   421 - 421   2023年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本耳科学会  

    researchmap

  • 外傷性鼓膜穿孔症例の検討

    佐久間 直子, 松延 毅, 臼倉 典宏, 鈴木 宏隆, 青木 秀治, 大久保 公裕

    日本耳科学会総会・学術講演会抄録集   33回   175 - 175   2023年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本耳科学会  

    researchmap

  • VZV髄膜炎を合併したRamsay-Hunt症候群の一例

    松延 毅, 香中 優美, 佐久間 直子, 鈴木 宏隆, 青木 秀治, 大久保 公裕

    日本耳鼻咽喉科免疫アレルギー感染症学会抄録集   2回   187 - 187   2022年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本耳鼻咽喉科免疫アレルギー感染症学会  

    researchmap

  • 異なる時期に発症した両側外耳道真珠腫症例

    佐久間 直子, 松延 毅, 森下 大樹, 鈴木 宏隆, 青木 秀治, 中川 千尋, 大久保 公裕

    日本耳科学会総会・学術講演会抄録集   30回   163 - 163   2020年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本耳科学会  

    researchmap

  • Sphenoid sinus development in patients with acquired middle ear cholesteatoma. 査読 国際誌

    Yasuhiro Arai, Daisuke Sano, Masahiro Takahashi, Goshi Nishimura, Kentaro Sakamaki, Naoko Sakuma, Masanori Komatsu, Nobuhiko Oridate

    Auris, nasus, larynx   47 ( 3 )   391 - 400   2020年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVE: In this study, we examine the relationship between developmental insufficiency of mastoid air cells and abnormal morphology of the paranasal sinuses in patients with chronic otitis media (COM) and acquired middle ear cholesteatoma (AMEC) using precise image assessment, in order to evaluate whether the anatomical features of paranasal sinuses has any impact on the pathogenesis in COM and AMEC. METHODS: A total of 127 patients, including 45 COM patients and 82 AMEC patients, were enrolled for this study. The existence of nasal septal deviation, the existence of paranasal sinus opacification, the modified Lund-Mackay score, the diameters of the paranasal sinuses, the Vidic classification, mastoid development, and cranial size were assessed by CT examination. A further 76 adult patients who underwent high-resolution CT imaging of their skull bone for other diseases were enrolled as the control. RESULTS: The AMEC group showed a significantly shorter sphenoid length (P < 0.01) and lower Vidic classification score (P < 0.01) compared to the control group in this study. In addition, we observed that patients with AMEC had less pneumatization of the mastoid air cells compared to the control individuals, and that the sphenoid length of the poor MC score group was significantly shorter than that of the good MC score group. CONCLUSION: Our results suggested that the developmental deficiency in sphenoid length caused by long-standing pediatric rhinosinusitis might indicate the potential of chronic middle ear inflammation in childhood and impact the pneumatization of mastoid air cells. Therefore, chronic rhinosinusitis during the childhood and adolescence might play a role in the pathophysiology of AMEC.

    DOI: 10.1016/j.anl.2019.09.008

    PubMed

    researchmap

  • Prevalence and clinical features of hearing loss caused by EYA4 variants. 査読 国際誌

    Jun Shinagawa, Hideaki Moteki, Shin-Ya Nishio, Kenji Ohyama, Koshi Otsuki, Satoshi Iwasaki, Shin Masuda, Chie Oshikawa, Yumi Ohta, Yasuhiro Arai, Masahiro Takahashi, Naoko Sakuma, Satoko Abe, Yuika Sakurai, Hirofumi Sakaguchi, Takashi Ishino, Natsumi Uehara, Shin-Ichi Usami

    Scientific reports   10 ( 1 )   3662 - 3662   2020年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Variants in the EYA4 gene are known to lead to autosomal dominant non-syndromic hereditary hearing loss, DFNA10. To date, 30 variants have been shown to be responsible for hearing loss in a diverse set of nationalities. To better understand the clinical characteristics and prevalence of DFNA10, we performed genetic screening for EYA4 mutations in a large cohort of Japanese hearing loss patients. We selected 1,336 autosomal dominant hearing loss patients among 7,408 unrelated Japanese hearing loss probands and performed targeted genome enrichment and massively parallel sequencing of 68 target genes for all patients. Clinical information of cases with mutations in EYA4 was gathered and analyzed from medical charts. Eleven novel EYA4 variants (three frameshift variants, three missense variants, two nonsense variants, one splicing variant, and two single-copy number losses) and two previously reported variants were found in 12 probands (0.90%) among the 1,336 autosomal dominant hearing loss families. The audiometric configuration of truncating variants tends to deteriorate for all frequencies, whereas that of non-truncating variants tends to show high-frequency hearing loss, suggesting a new correlation between genotype and phenotype in DFNA10. The rate of hearing loss progression caused by EYA4 variants was considered to be 0.63 dB/year, as found in this study and previous reports.

    DOI: 10.1038/s41598-020-60259-0

    PubMed

    researchmap

  • Mutational Spectrum and Clinical Features of Patients with LOXHD1 Variants Identified in an 8074 Hearing Loss Patient Cohort. 査読 国際誌

    Karuna Maekawa, Shin-Ya Nishio, Satoko Abe, Shin-Ichi Goto, Yohei Honkura, Satoshi Iwasaki, Yukihiko Kanda, Yumiko Kobayashi, Shin-Ichiro Oka, Mayuri Okami, Chie Oshikawa, Naoko Sakuma, Hajime Sano, Masayuki Shirakura, Natsumi Uehara, Shin-Ichi Usami

    Genes   10 ( 10 )   2019年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Variants of the LOXHD1 gene, which are expressed in hair cells of the cochlea and vestibule, have been reported to cause a progressive form of autosomal recessive non-syndromic hereditary hearing loss, DFNB77. In this study, genetic screening was conducted on 8074 Japanese hearing loss patients utilizing massively parallel DNA sequencing to identify individuals with LOXHD1 variants and to assess their phenotypes. A total of 28 affected individuals and 21 LOXHD1 variants were identified, among which 13 were novel variants. A recurrent variant c.4212 + 1G > A, only reported in Japanese patients, was detected in 18 individuals. Haplotype analysis implied that this variation occurred in a mutational hot spot, and that multiple ancestors of Japanese population had this variation. Patients with LOXHD1 variations mostly showed early onset hearing loss and presented different progression rates. We speculated that the varying severities and progression rates of hearing loss are the result of environmental and/or other genetic factors. No accompanying symptoms, including vestibular dysfunction, with hearing loss were detected in this study. Few studies have reported the clinical features of LOXHD1-gene associated hearing loss, and this study is by far the largest study focused on the evaluation of this gene.

    DOI: 10.3390/genes10100735

    PubMed

    researchmap

  • Postoperative Bio-Chemoradiotherapy Using Cetuximab and Docetaxel in Patients With Cis-Platinum-Intolerant Core High-Risk Head and Neck Cancer: Protocol of a Phase 2 Nonrandomized Clinical Trial. 査読 国際誌

    Goshi Nishimura, Hiromitsu Hatakeyama, Osamu Shiono, Masataka Taguri, Masanori Komatsu, Daisuke Sano, Naoko Sakuma, Kenichiro Yabuki, Yasuhiro Arai, Kunihiko Shibata, Yoshihiro Chiba, Teruhiko Tanabe, Nobuhiko Oridate

    JMIR research protocols   7 ( 8 )   e11003   2018年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: We confirmed the safety of postoperative bio-chemoradiotherapy using cetuximab and docetaxel in a small number of patients with cis-platinum-intolerant core high-risk head and neck cancer. OBJECTIVE: To assess treatment efficacy, we planned a phase 2 study of postoperative bio-chemoradiotherapy for patients with cis-platinum-intolerant core high-risk head and neck cancer and will compare the results to those of previously collected radiotherapy data. METHODS: Patients who underwent definitive surgery for oral cavity, laryngeal, oropharyngeal, or hypopharyngeal advanced cancer, whose postoperative pathological results indicated core high risk for recurrence (eg, positive margin in the primary site or extranodal extension) and who were cis-platinum-intolerant, will undergo postoperative bio-chemoradiotherapy. The primary end point is 2-year disease-free survival. RESULTS: The expected 2-year disease-free survival is set at 55%, and the calculated sample size is 35 patients, according to a statistical analysis based on previous reports. CONCLUSIONS: This treatment method is expected to improve the survival rate of patients with severe head and neck cancer. TRIAL REGISTRATION: UMIN Clinical Trials Registry UMIN000031835; https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ ctr_view.cgi?recptno=R000036355 (Archived by WebCite at http://www.webcitation.org/71fejVjMr).

    DOI: 10.2196/11003

    PubMed

    researchmap

  • Cochlear volume as a predictive factor for residual-hearing preservation after conventional cochlear implantation. 査読 国際誌

    Masahiro Takahashi, Yasuhiro Arai, Naoko Sakuma, Kenichiro Yabuki, Daisuke Sano, Goshi Nishimura, Nobuhiko Oridate, Shin-Ichi Usami

    Acta oto-laryngologica   138 ( 4 )   345 - 350   2018年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVE: The preservation of residual hearing after conventional cochlear implantation (CI) is frequently observed when atraumatic soft surgery is adopted. The purpose of this study was to elucidate the predictive factors for residual hearing preservation after atraumatic CI. PATIENTS: This study included 46 patients who underwent CI based on an atraumatic technique using a standard-length flexible electrode implant through a round window approach. MAIN OUTCOME MEASURE: Cochlear volume was measured using magnetic resonance imaging (MRI). Cochlear duct length (CDL) was taken as the length of the scala media measured using computed tomography (CT). The association between residual hearing preservation and cochlear volume/CDL was then examined. RESULT: Cochlear volume and CDL were significantly larger in patients with complete hearing preservation than in those with hearing loss. Multivariate logistic regression analysis revealed that cochlear volume was a significant predictive factor for residual hearing preservation. CONCLUSION: Residual hearing preservation after conventional CI was observed in patients with a larger cochlear volume and longer CDL. Cochlear volume could be a predictive factor for residual hearing preservation after conventional CI.

    DOI: 10.1080/00016489.2017.1393840

    PubMed

    researchmap

  • An effective screening strategy for deafness in combination with a next-generation sequencing platform: a consecutive analysis. 査読 国際誌

    Naoko Sakuma, Hideaki Moteki, Masahiro Takahashi, Shin-ya Nishio, Yasuhiro Arai, Yukiko Yamashita, Nobuhiko Oridate, Shin-ichi Usami

    Journal of human genetics   61 ( 3 )   253 - 61   2016年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The diagnosis of the genetic etiology of deafness contributes to the clinical management of patients. We performed the following four genetic tests in three stages for 52 consecutive deafness subjects in one facility. We used the Invader assay for 46 mutations in 13 genes and Sanger sequencing for the GJB2 gene or SLC26A4 gene in the first-stage test, the TaqMan genotyping assay in the second-stage test and targeted exon sequencing using massively parallel DNA sequencing in the third-stage test. Overall, we identified the genetic cause in 40% (21/52) of patients. The diagnostic rates of autosomal dominant, autosomal recessive and sporadic cases were 50%, 60% and 34%, respectively. When the sporadic cases with congenital and severe hearing loss were selected, the diagnostic rate rose to 48%. The combination approach using these genetic tests appears to be useful as a diagnostic tool for deafness patients. We recommended that genetic testing for the screening of common mutations in deafness genes using the Invader assay or TaqMan genotyping assay be performed as the initial evaluation. For the remaining undiagnosed cases, targeted exon sequencing using massively parallel DNA sequencing is clinically and economically beneficial.

    DOI: 10.1038/jhg.2015.143

    PubMed

    researchmap

  • Gene expression profiles of the cochlea and vestibular endorgans: localization and function of genes causing deafness. 査読 国際誌

    Shin-Ya Nishio, Mitsuru Hattori, Hideaki Moteki, Keita Tsukada, Maiko Miyagawa, Takehiko Naito, Hidekane Yoshimura, Yoh-Ichiro Iwasa, Kentaro Mori, Yutaka Shima, Naoko Sakuma, Shin-Ichi Usami

    The Annals of otology, rhinology, and laryngology   124 Suppl 1   6S-48S   2015年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVES: We sought to elucidate the gene expression profiles of the causative genes as well as the localization of the encoded proteins involved in hereditary hearing loss. METHODS: Relevant articles (as of September 2014) were searched in PubMed databases, and the gene symbols of the genes reported to be associated with deafness were located on the Hereditary Hearing Loss Homepage using localization, expression, and distribution as keywords. RESULTS: Our review of the literature allowed us to systematize the gene expression profiles for genetic deafness in the inner ear, clarifying the unique functions and specific expression patterns of these genes in the cochlea and vestibular endorgans. CONCLUSIONS: The coordinated actions of various encoded molecules are essential for the normal development and maintenance of auditory and vestibular function.

    DOI: 10.1177/0003489415575549

    PubMed

    researchmap

  • Novel PTPRQ mutations identified in three congenital hearing loss patients with various types of hearing loss. 査読 国際誌

    Naoko Sakuma, Hideaki Moteki, Hela Azaiez, Kevin T Booth, Masahiro Takahashi, Yasuhiro Arai, A Eliot Shearer, Christina M Sloan, Shin-Ya Nishio, Diana L Kolbe, Satoshi Iwasaki, Nobuhiko Oridate, Richard J H Smith, Shin-Ichi Usami

    The Annals of otology, rhinology, and laryngology   124 Suppl 1   184S-92S   2015年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVES: We present 3 patients with congenital sensorineural hearing loss (SNHL) caused by novel PTPRQ mutations, including clinical manifestations and phenotypic features. METHODS: Two hundred twenty (220) Japanese subjects with SNHL from unrelated and nonconsanguineous families were enrolled in the study. Targeted genomic enrichment with massively parallel DNA sequencing of all known nonsyndromic hearing loss genes was performed to identify the genetic cause of hearing loss. RESULTS: Four novel causative PTPRQ mutations were identified in 3 cases. Case 1 had progressive profound SNHL with a homozygous nonsense mutation. Case 2 had nonprogressive profound SNHL with a compound heterozygous mutation (nonsense and missense mutation). Case 3 had nonprogressive moderate SNHL with a compound heterozygous mutation (missense and splice site mutation). Caloric test and vestibular evoked myogenic potential (VEMP) test showed vestibular dysfunction in Case 1. CONCLUSION: Hearing loss levels and progression among the present cases were varied, and there seem to be no obvious correlations between genotypes and the phenotypic features of their hearing loss. The PTPRQ mutations appeared to be responsible for vestibular dysfunction.

    DOI: 10.1177/0003489415575041

    PubMed

    researchmap

  • [The accuracy of evaluating the response of metastatic lymph nodes after concurrent chemoradiotherapy in patients with head and neck squamous cell carcinoma]. 査読

    Goshi Nishimura, Masanori Komatsu, Takahide Taguchi, Masahiro Takahashi, Daisuke Sano, Naoko Sakuma, Yasuhiro Arai, Hideaki Takahashi, Yasuko Tanaka, Kae Sawakuma, Nobuhiko Oridate

    Nihon Jibiinkoka Gakkai kaiho   117 ( 7 )   899 - 906   2014年7月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Concurrent chemoradiotherapy (CCRT) is used to treat advanced head and neck cancer. The accuracy of evaluating lymph nodes metastases following CCRT is important for subsequent therapy. PATIENTS AND METHODS: Patients were divided into two groups according to the nodal status, the complete response (CR) and the non-CR groups, as determined by imaging and fine-needle aspiration cytology (FNAC) performed 4-8 weeks after the CCRT, and the findings were compared with the status 6 months after the treatment completion. RESULTS: The sensitivity, the specificity, positive predictive value, negative predictive value and accuracy of each evaluation method were as follows: 66.7%, 73.5%, 26.7%, 93.8% and 72.5%, respectively, for computer tomography (CT) and magnetic resonance imaging (MRI); 91.7%, 69.9%, 30.6%, 98.3% and 72.6% for ultrasonography (US) ; 50.0%, 96.4%, 66.7%, 93.0% and 90.5% for fluorodeoxyglucose-positron emission tomography (FDG-PET) or PET-CT; and 68.4%, 96.1%, 81.3%, 92.5% and 90.6% for FNAC. CONCLUSION: To evaluate the response of lymph node(s) treated by CCRT, US is useful as a positive screening tool and FDG-PET and PET-CT as negative screening tools. FNAC is useful in evaluating suspicious lymph nodes in both positive and negative cases.

    PubMed

    researchmap

  • Treatment results and prognostic factors for advanced squamous cell carcinoma of the hypopharynx treated with concurrent chemoradiotherapy. 査読 国際誌

    Takahide Taguchi, Goshi Nishimura, Masahiro Takahashi, Masanori Komatsu, Daisuke Sano, Naoko Sakuma, Ken-ichiro Yabuki, Yasuhiro Arai, Hideaki Takahashi, Masaharu Hata, Izumi Koike, Nobuhiko Oridate

    Cancer chemotherapy and pharmacology   73 ( 6 )   1147 - 54   2014年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    PURPOSE: The purpose of the study is to review our experience with concurrent chemoradiotherapy (CCRT) for patients with advanced resectable squamous cell carcinoma(SCC) of the hypopharynx and to evaluate the factors affecting survival and larynx preservation. STUDY DESIGN: Retrospective study. METHODS AND MATERIALS: T he records of 102 patients with Stage III or IV resectable SCC of the hypopharynx treated with CCRT between January 1998 and August 2010 were reviewed. Of the 102 patients, 62 were treated with high dose regimens including cisplatin, 5-fluorouracil, methotrexate, leucovorin or docetaxel, cisplatin, and 5-fluorouracil. The remaining 40 were treated with low-dose regimens including carboplatin and uracil-tegafur, weekly docetaxel, or S-1. Radiotherapy was delivered 5 days a week using a single daily fraction of 1.8–2.0 Gray (Gy), to a total dose of 64.8–70.2 Gy. Overall survival (OS), disease-specific survival (DSS), and DSS with larynx preservation were estimated using Kaplan–Meier methods. The log-rank test and Cox proportional hazards regression were used to identify significant prognostic factors for OS, DSS, and DSS with larynx preservation. RESULTS: The 5-year OS and DSS for all patients treated with CCRT were 51.3 and 64.3 %, respectively. The 5-year DSS with larynx preservation was 55.5 %. On multivariate analysis, the content of chemotherapy was a significant predictor of OS and DSS for patients undergoing CCRT ; N stage was a significant prognostic factor for DSS and larynx preservation. CONCLUSION: T he treatment method including the indication for CCRT may be determined by the contents of the chemotherapy and the N stages of SCC of the hypopharynx.

    PubMed

    researchmap

  • Concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck. 査読 国際誌

    Masanori Komatsu, Osamu Shiono, Takahide Taguchi, Yasunori Sakuma, Goushi Nishimura, Daisuku Sano, Naoko Sakuma, Kenichiro Yabuki, Yasuhiro Arai, Masahiro Takahashi, Junichi Isitoya, Nobuhiko Oridate

    Japanese journal of clinical oncology   44 ( 5 )   416 - 21   2014年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVE: Compared with radiotherapy alone, concurrent chemoradiotherapy significantly improves survival rates for patients with squamous cell carcinoma of the head and neck. The aim of this study was to retrospectively evaluate the efficacy, toxicity and long-term prognosis of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil chemotherapy. METHODS: A total of 140 patients were enrolled and evaluated. Patients were received two cycles of docetaxel, cisplatin and 5-fluorouracil chemotherapy (docetaxel [50 mg/m(2): Day 1], cisplatin [60 mg/m(2): Day 4] and continuous 5-fluorouracil [600 mg/m(2)/day: Days 1-5]) during definitive radiotherapy. RESULTS: The overall response rate was 97.1%. The 3 and 5-year overall survival rates were 83.3 and 79.2%, respectively. The 3 and 5-year disease-specific survival rates were 84.2 and 80.0%, respectively. Among patients with laryngeal or hypopharyngeal carcinoma, the 5-year laryngectomy-free survival rate was 64.9%. CONCLUSIONS: Concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil showed excellent survival and organ preservation rates for the patients with locally advanced squamous cell carcinoma of the head and neck.

    DOI: 10.1093/jjco/hyu026

    PubMed

    researchmap

  • Treatment results and prognostic factors for advanced squamous cell carcinoma of the larynx treated with concurrent chemoradiotherapy. 査読 国際誌

    Takahide Taguchi, Goshi Nishimura, Masahiro Takahashi, Masanori Komatsu, Daisuke Sano, Naoko Sakuma, Yasuhiro Arai, Yukiko Yamashita, Osamu Shiono, Mariko Hirama, Yasunori Sakuma, Jun-ichi Ishitoya, Masaharu Hata, Ichiro Ogino, Nobuhiko Oridate

    Cancer chemotherapy and pharmacology   72 ( 4 )   837 - 43   2013年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVE: To review our experience with concurrent chemoradiotherapy (CCRT) for patients with advanced resectable squamous cell carcinoma (SCC) of the larynx and to evaluate the factors affecting survival and larynx preservation. STUDY DESIGN: Retrospective study. SUBJECTS AND METHODS: The records of 102 patients with stage III or IV resectable SCC of the larynx treated with CCRT between February 1994 and March 2009 were reviewed. Of 102 patients, 59 were treated with high-dose regimens, including cisplatin, 5-fluorouracil (5-FU), methotrexate, and leucovorin or docetaxel, cisplatin, and 5-FU, and 43 were treated with low-dose regimens, including carboplatin and uracil-tegafur or S-1. Radiotherapy was delivered 5 days a week using a single daily fraction of 1.8–2.0 Gray (Gy), to a total dose of 66.0–70.2 Gy. Overall survival (OS), disease-specific survival (DSS), and DSS with larynx preservation were estimated using Kaplan–Meier methods. The log-rank test and Cox proportional hazards regression were used to identify significant prognostic factors for DSS and DSS with larynx preservation. RESULTS: The 5-year OS and DSS for all patients treated with CCRT were 63.9 and 70.7 %, respectively. The 5-year DSS with larynx preservation was 54.1 %. On multivariate analysis, N stage, synchronous multiple primary cancers, and the contents of chemotherapy were significant predictors of OS for patients undergoing CCRT; T stage, N stage, and the contents of chemotherapy were significant prognostic factors for larynx preservation. CONCLUSION: The treatment method including the indication for CCRT may be determined by the contents of the chemotherapy and the T and N stages of laryngeal SCC. It is important to diagnose multiple synchronous primary cancers before CCRT.

    PubMed

    researchmap

  • [A case report: a repeated cerebrospinal fluid otorrhea]. 査読

    Yasuhiro Arai, Naoko Sakuma, Daisuke Sano, Masahiro Takahashi, Hideki Matsuda, Ryo Ikoma, Sayaka Sakane, Kazutomo Niwa, Iemasa Cho, Junichi Ishitoya

    Nihon Jibiinkoka Gakkai kaiho   116 ( 3 )   161 - 4   2013年3月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    Cerebrospinal fluid (CSF) otorrhea, leakage of CSF through the ear structures, may occur from a traumatic or operative defect in the skull, tumor, cholesteatoma, or congenital anomalies. A case of repeated CSF otorrhea is uncommon. In this report, we presented a case of a repeated CSF otorrhea which occurred a decade after the first middle ear surgery for chronic otitis media. The first CSF leakage, which might have been due to bone defects in the tegmen at the first middle ear sutgery, was surgically repaired using a transmastoid approach. However, CSF leakage with a meningoencephalocele occurred again 8 years after our first surgery for the CSF and the fistula was repaired using a transmiddle cranial fossa approach. Although 2 years have passed since the surgery, the CSF leakage has not recurred.

    PubMed

    researchmap

  • Treatment evaluation of metastatic lymph nodes after concurrent chemoradiotherapy in patients with head and neck squamous cell carcinoma. 査読 国際誌

    Goshi Nishimura, Hideki Matsuda, Takahide Taguchi, Masahiro Takahashi, Masanori Komatsu, Daisuke Sano, Naoko Sakuma, Yasuhiro Arai, Hideaki Takahashi

    Anticancer research   32 ( 2 )   595 - 600   2012年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Concurrent chemoradiotherapy (CCRT) is used to treat advanced head and neck cancer. The accuracy of evaluating lymph nodes metastases following CCRT is important for subsequent therapy. PATIENTS AND METHODS: Patients were divided into two groups, the complete response (CR) and the non-CR groups, as determined by imaging and fine-needle aspiration cytology (FNAC) performed 4-8 weeks after the CCRT, and the findings were compared with the clinical characteristics. RESULTS: The sensitivity and the specificity of each evaluation method were as follows: 52.9% and 74.2%, respectively, for computer tomography (CT) and magnetic resonance imaging (MRI); 88.2% and 66.1% for ultrasonography (US); 35.3% and 96.0% for fluorodeoxyglucose-positron emission tomography (FDG-PET) or PET-CT; and 71.4% and 95.6% for FNAC. CONCLUSION: To evaluate the response of lymph node(s) treated by CCRT, US is useful as a positive screening tool and FDG-PET and PET-CT as negative screening tools. FNAC is useful in evaluating suspicious lymph nodes in both positive and negative cases.

    PubMed

    researchmap

  • Efficacy of fluoro-2-deoxy-D-glucose positron emission tomography to evaluate responses to concurrent chemoradiotherapy for head and neck squamous cell carcinoma. 査読 国際誌

    Makiko Mori, Mamoru Tsukuda, Choichi Horiuchi, Hideki Matsuda, Takahide Taguchi, Masahiro Takahashi, Goshi Nishimura, Masanori Komatsu, Tatsuo Niho, Naoko Sakuma, Kunihiko Shibata, Satoko Sugisaki

    Auris, nasus, larynx   38 ( 6 )   724 - 9   2011年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVE: This study evaluates the utility of fluorodeoxyglucose-positron emission tomography (FDG-PET) in patients with head and neck squamous cell carcinoma (HNSCC) who received concurrent chemoradiotherapy (CCRT). METHODS: Sixty-five patients were recruited for this study between November 2002 and April 2007. The FDG-PET scan was performed before treatment and 4-6 weeks after treatment. RESULTS: The mean of maximum standardized uptake value (SUVmax) before treatment at the primary tumor site was 8.1 (range, 2-22). The sensitivity of FDG-PET for the diagnosis of primary tumor site was 98%. The mean of SUVmax after treatment was 2.6 (range, 2-5). The sensitivity, specificity, and accuracy of FDG-PET for the diagnosis of primary tumor site after treatment were 100%, 40%, and 46%, respectively. The mean of SUVmax before treatment at the nodal site was 4.7 (range, 2-16). The mean of SUVmax after treatment was 2.0 (range, 2-6.7). The pre-treatment SUVmax of T2, T3, and T4 stages were significantly higher than that of the T1 stage. The N stage had no correlation in terms of the pre-treatment nodal site SUVmax. CONCLUSION: Our results indicate that FDG-PET is a useful imaging method for evaluating the response of CCRT in patients with HNSCC. However, performing FDG-PET 4-6 weeks after treatment may be too early as it may give false-positive results due to fibrosis and scarring.

    DOI: 10.1016/j.anl.2011.04.013

    PubMed

    researchmap

  • Efficacy and toxicity of concurrent chemoradiotherapy in patients with advanced oropharyngeal squamous cell carcinoma. 査読 国際誌

    Makiko Mori, Mamoru Tsukuda, Hideki Matsuda, Choichi Horiuchi, Takahide Taguchi, Masahiro Takahashi, Goshi Nishimura, Masanori Komatsu, Tatsuo Niho, Naoko Sakuma, Asako Miyakoshi, Yasuhiro Isono, Sayaka Iwahana

    Cancer chemotherapy and pharmacology   68 ( 4 )   855 - 62   2011年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    PURPOSE: The aim of this study was to evaluate the feasibility and toxicity of concurrent chemoradiotherapy (CCRT) with docetaxel, cisplatin (CDDP) and 5-fluorouracil (5-FU) (TPF regimen) or with CDDP, 5-FU, methotrexate and leucovorin (PFML regimen) in previously untreated patients with advanced oropharyngeal squamous cell carcinoma (SCC). METHODS: Fifty-six eligible patients with stage III or IV oropharyngeal SCC were treated with CCRT. Forty-four patients were men and 12 were women, and the average age of the patients was 58.8 years (range, 37-72 years). In the TPF group, patients received CCRT with the TPF regimen [docetaxel (50 mg/m(2), day 1), CDDP (60 mg/m(2), day 4) and a continuous 5-FU infusion (600 mg/m(2)/day, days 1-5)]. In the PFML group, patients received CCRT with the PFML regimen [CDDP (60 mg/m(2), day 4), a continuous 5-FU infusion (600 mg/m(2)/day, days 1-5), methotrexate (30 mg/m(2), day 1) and leucovorin (10 mg/m(2)/day, days 1-5)]. The total radiation dose was between 66.6 and 70.2 Gy. RESULTS: The overall 5-year survival rate was 64.6% in all patients, 68.6% in the resectable group and 47.4% in the unresectable group. The 5-year disease-specific survival rate was 72.2% in all patients, 78.1% in the resectable group and 47.7% in the unresectable group. Regarding clinical stage, the 5-year disease-specific survival rates were 91% in stage III, 72% in stage IVa and 44% in stage IVb. CONCLUSION: CCRT with TPF or PFML regimen for advanced oropharyngeal SCC is tolerable and effective, especially in patients with resectable disease.

    DOI: 10.1007/s00280-010-1551-2

    PubMed

    researchmap

  • [A case of head and neck squamous cell carcinoma suffering from acute renal failure after methotrexate administrator]. 査読

    Junichi Nagao, Mamoru Tsukuda, Takashi Yoshida, Naoko Sakuma, Hideki Matsuda, Yasukazu Mikami

    Gan to kagaku ryoho. Cancer & chemotherapy   32 ( 6 )   821 - 3   2005年6月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    A 56-year-old man was hospitalized for evaluation of left neck tumor. The biopsy of neck lymph node showed a squamous cell carcinoma. Since no primary lesion was detected, the diagnosis was primary unknown neck lymph node metastasis. The first course of our chemotherapeutic regimen consisted of CDDP, 5-FU, MTX and LV. After MTX infusion, the level of serum creatinine increased. Based on laboratory data, we diagnosed acute renal failure caused by MTX and added the infusion of Ringer and LV. The serum creatinine level decreased to the level before chemotherapy. In the second course, chemotherapy with only CDDP and 5-FU was administered, and the level of serum creatinine did not increase. In the present case, suitable intravenous drip infusion of Ringer's injection prevented irreversible renal dysfunction. Since the laboratory data did not show dysfunction of uriniferous tubule and renal glomerulus, we considered allergic nephritis as a possibility.

    PubMed

    researchmap

▼全件表示

MISC

▼全件表示

共同研究・競争的資金等の研究課題

  • 先天性難聴児における遺伝子解析と言語発達の関連性

    研究課題/領域番号:18K16899  2018年4月 - 2021年3月

    日本学術振興会  科学研究費助成事業 若手研究  若手研究

    佐久間 直子

      詳細を見る

    配分額:4160000円 ( 直接経費:3200000円 、 間接経費:960000円 )

    先天性難聴は新生児1000名に1名認められる比較的頻度の高い障害であるが、 その50%以上が遺伝性難聴と報告されている。難聴は外耳から中耳に原因のある伝音難聴、内耳から中枢性に原因のある感音難聴、その両者に原因のある混合性難聴に大きく分類されるが、遺伝性難聴で現在同定されている遺伝子の多くは内耳(蝸牛)に発現していることより、感音難聴を呈する。そのため、中耳疾患や難聴の原因とされる先天性感染症を伴わない小児の感音または混合難聴症例の中に遺伝性難聴が含まれると推察される。2018年4月から2019年3月の期間内に難聴を主訴に横浜市立大学附属市民総合医療センター耳鼻咽喉科外来を受診した患者のうち、聴力検査を施行した4歳から12歳までの症例は127例であった。そのうち中耳疾患による伝音性難聴と機能性難聴の症例は合わせて57例であった。残りの70例のうち、経過や画像評価などにより先天性感音難聴または混合性難聴と診断された症例は66例であった。66例のうち1例は先天性サイトメガロウイルス感染症による難聴と診断された。よって遺伝性難聴の可能性があると考えられたのは65例であった。65例の中で、両側感音難聴または混合難聴は58例であり、残りの7例は一側性感音難聴であった。また65例の中で、遺伝学的検査を施行したのは両側性感音または混合難聴26例、一側性感音難聴1例であった。2019年3月までの時点で14例が遺伝学的検査にて遺伝子変異が同定されている。

    researchmap